The trading price of Atea Pharmaceuticals Inc. (NASDAQ:AVIR) closed higher on Tuesday, July 20, closing at $25.03, 0.52% higher than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $23.285 and $25.68. The company’s P/E ratio in the trailing 12-month period was 98.93. In examining the 52-week price action we see that the stock hit a 52-week high of $94.17 and a 52-week low of $18.72. Over the past month, the stock has gained 7.01% in value.
Atea Pharmaceuticals Inc., whose market valuation is $1.99 billion at the time of this writing, is expected to release its quarterly earnings report Mar 30, 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by $0 per share this quarter, however they have predicted annual earnings per share of $0.49 for 2021 and $12.06 for 2022. It means analysts are expecting annual earnings per share growth of 196.10% this year and 2,361.20% next year.
From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2021 is $293.77 million. The company’s revenue is forecast to grow by 504.10% over what it did in 2021.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Atea Pharmaceuticals Inc. No upward and no downward comments were posted in the last 7 days.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned AVIR a recommendation rating is 3. Out of them, 0 rate it a Hold, while 3 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Atea Pharmaceuticals Inc. (AVIR) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that AVIR’s price is currently 7.83% off the SMA20 and 11.27% off the SMA50. The RSI metric on the 14-day chart is currently showing 56.12, and weekly volatility stands at 9.04%. When measured over the past 30 days, the indicator reaches 8.75%. Atea Pharmaceuticals Inc. (NASDAQ:AVIR)’s beta value is currently sitting at 0, while the Average True Range indicator is currently displaying 1.95. With analysts defining $31.00-$104.00 as the low and high price targets, we arrive at a consensus price target of $56.67 for the trailing 12-month period. The current price is about -23.85% off the estimated low and -315.5% off the forecast high, based on this estimate. Investors will be thrilled if AVIR’s share price rises to $35.00, which is the median consensus price. At that level, AVIR’s share price would be -39.83% below current price.
To see how Atea Pharmaceuticals Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: AVIR stock’s performance was 0.52% in the latest trading. Atea Pharmaceuticals Inc. has a P/E ratio of 98.93. Also in last trading session, the S&P 500 Index has surged 1.52%, while the Dow Jones Industrial also saw a positive session, up 1.62% on the day.
An evaluation of the daily trading volume of Atea Pharmaceuticals Inc. (NASDAQ:AVIR) indicates that the 3-month average is 1.40 million. However, this figure has increased over the past 10 days to an average of 1.03 million.
Currently, records show that 82.58 million of the company’s shares remain outstanding. The insiders hold 18.48% of outstanding shares, whereas institutions hold 63.40%. The stats also highlight that short interest as of Apr 14, 2021, stood at 4.25 million shares, resulting in a short ratio of 11.26 at that time. From this, we can conclude that short interest is 5.14% of the company’s total outstanding shares. It is noteworthy that short shares in April were up slightly from the previous month’s figure, which was 2.24 million. However, since the stock’s price has seen -40.09% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.